PROF vs EDAP

Both EDAP TMS S.A. (NasdaqGM: EDAP) and Profound Medical Corp. (NasdaqCM: PROF) operate in the medical device sector, specifically focusing on innovative, minimally invasive treatments for urological conditions, particularly prostate-related issues. While they share a similar market focus, a closer look at Fintel's data reveals distinct profiles.

Company Overview & Product Focus

• EDAP TMS S.A. specializes in high-intensity focused ultrasound (HIFU) and shock wave technologies for various urological diseases, including prostate tissue ablation with its Focal One® Robotic HIFU platform.1 The company recently secured a €36 million credit facility from the European Investment Bank to expand this platform and develop new clinical indications.2
• Profound Medical Corp. offers customizable, incision-free therapies, with its flagship TULSA-PRO® system combining real-time MRI and robotically-driven transurethral ultrasound for prostate ablation. Profound also commercializes Sonalleve® for uterine fibroids and bone metastases.3

Key Financial and Ownership Metrics

• Market Capitalization: Profound Medical Corp. has a market capitalization of $166.49 million as of August 8, 2025.3 While EDAP's direct market cap isn't explicitly stated in the provided snippets for its NasdaqGM listing, its institutional value is $31.039 million (as of MRQ),4 suggesting a smaller overall valuation compared to PROF.
• Institutional Ownership: Profound Medical Corp. has 56 institutional owners holding 13,700,269 shares, representing an average portfolio allocation of 0.4316%.5 EDAP TMS S.A. has 39 institutional owners holding 16,015,498 shares, with an average portfolio allocation of 0.0770%.4 This indicates a higher number of institutions and a larger average allocation percentage in PROF.
• Share Price Performance (1-Year): EDAP has experienced a significant decline of 74.49% from August 7, 2024, to August 6, 2025.4 Profound Medical Corp. also saw a decline of 42.41% over the past year.3
• Piotroski F-Score: Profound Medical Corp. holds a Piotroski F-Score of 5.00/9,3 slightly higher than EDAP's 4.00/9.1 A higher score generally suggests better financial health based on nine criteria.
• Analyst Sentiment: The average one-year price target for EDAP is $5.86 (as of Aug 5, 2025),1 while for Profound Medical Corp. (NasdaqCM: PROF), it is $11.32 (as of July 17, 2025).3

In summary, both companies are engaged in advanced medical device technology for urological treatments. Profound appears to have a larger market presence and slightly stronger financial health indicators based on the Piotroski score and institutional allocation, while EDAP has recently secured significant financing for its growth initiatives. Investors interested in this space might consider the specific technological advantages and market penetration of each company's core products.

Analyze the historical institutional ownership trends for both EDAP and PROF over the last two years to identify accumulation or distribution patterns.

The request to analyze historical institutional ownership trends for EDAP and PROF over the last two years is a valuable step in understanding smart money movements. While the Fintel snippets provide a snapshot and recent quarterly changes, a deeper dive into the available data reveals distinct patterns for each company.

Institutional Ownership Trends: EDAP vs. PROF

EDAP TMS S.A. (NasdaqGM: EDAP) Institutional ownership data for EDAP indicates a mixed, yet slightly distributive, pattern in recent quarters. The company currently has 39 institutional owners, which represents a modest 2.63% increase quarter-over-quarter (MRQ). However, the average portfolio allocation to EDAP by these institutions has seen a significant decline of 30.32% MRQ. Despite this, the total institutional shares held increased slightly by 0.72% (or 0.11 million shares) in the most recent quarter, totaling 16,015,498 shares.1 This suggests that while more institutions might be initiating small positions or maintaining existing ones, their overall conviction, as measured by portfolio allocation, has decreased. This trend coincides with a substantial 74.49% decline in EDAP's share price over the past year.1

Profound Medical Corp. (NasdaqCM: PROF) Profound Medical Corp. exhibits a more pronounced distributive pattern in its institutional ownership over the recent quarter. The number of institutional owners decreased by 11.11% MRQ, bringing the total to 56.2 Concurrently, the total institutional shares held also saw a reduction of 5.69% (or 0.83 million shares) MRQ, now standing at 13,339,680 shares.2 Interestingly, for the institutions that remain or have recently entered, the average portfolio allocation to PROF increased by 25.51% MRQ.2 This could imply that while some institutions have exited, those with remaining or new positions have a higher conviction in the stock, making it a larger part of their portfolios. Specific 13G/A filings show both accumulation (e.g., Gagnon Securities LLC increasing shares by 15.19% in January 2025) and distribution (e.g., Letko, Brosseau & Associates Inc. closing its position in October 2024).2 Profound's share price has also experienced a decline, albeit less severe than EDAP's, falling by 41.06% over the last year.2

In summary, both companies have seen significant share price depreciation over the past year. EDAP shows a slight increase in the number of institutional holders and total shares, but a notable decrease in average portfolio allocation, suggesting a cautious approach from institutions. PROF has experienced a decrease in both the number of institutional holders and total shares, indicating a net distribution, despite an increased average allocation from its remaining or new institutional investors.

Compare treatment current location counts and extrapolate future growth rates.

Both EDAP TMS S.A. (EDAP) and Profound Medical Corp. (PROF) are actively expanding their presence in the urological medical device market, particularly concerning prostate treatments. While direct comparable metrics for "treatment current location counts" are not equally available from the provided data, we can analyze their reported installed bases and growth strategies.

Treatment Location Counts and Growth Extrapolation

Profound Medical Corp. (PROF) Profound Medical's TULSA-PRO® system has a clearly reported installed base. As of the third quarter of 2025, the company's TULSA-PRO® installed base stood at 67 systems, an increase from 60. Profound anticipates reaching at least 75 installed systems by the end of 2025.1 Furthermore, Profound has a robust sales pipeline, with 80 new TULSA-PRO® systems classified within the "Verify, Negotiate and Contracting" stages as of Q2 2025.2 The company also reported that over 3,000 global TULSA-PRO® procedures have been performed by more than 100 physicians across over 30 commercial and 20 clinical research sites.3

In terms of growth rates, Profound anticipates total revenues for Q3 2025 to be between $5.2 million and $5.3 million, representing significant year-over-year growth of 84% to 87%.1 The utilization of existing TULSA-PRO® systems is also growing, with "same store" procedure volumes up 10% sequentially from Q1 2025.2 This indicates both an expanding footprint and increased usage of existing installations.

EDAP TMS S.A. (EDAP) Specific current "installed base" numbers for EDAP's Focal One® Robotic HIFU platform are not explicitly detailed in the provided Fintel search results. However, EDAP's growth strategy is clearly focused on the global expansion of this platform. The company recently secured a €36 million multi-tranche credit facility from the European Investment Bank (EIB) specifically to support the continued global expansion of its Focal One® platform and to accelerate the development of new clinical indications.4 This financing underscores a strategic push for broader market penetration and technological advancement. EDAP's Focal One® is recognized for its potential to expand beyond prostate cancer to multiple indications.4

While a direct installed base count is not available, analyst forecasts project EDAP's annual revenue to reach $303 million by 2031.5 This long-term revenue projection suggests an expectation of substantial future growth and adoption of its technology, likely driven by the expansion initiatives funded by the EIB credit facility.

Summary of Growth Outlook

Profound Medical provides more granular detail on its current installed base and near-term sales pipeline, along with strong recent revenue growth figures. EDAP, while not providing a specific installed base count in the available data, has secured significant financing to fuel its global expansion and product development, pointing to a strategic long-term growth trajectory in the same market. Investors should consider the transparency and specificity of Profound's reported growth metrics against EDAP's strategic financing for future expansion.

Analyze the geographical distribution of installed systems for both PROF and EDAP to identify key market focuses and expansion opportunities.

Both EDAP TMS S.A. (EDAP) and Profound Medical Corp. (PROF) are strategically expanding their innovative urological treatment systems, but their geographical focus and reported distribution metrics differ.

Geographical Distribution of Installed Systems

Profound Medical Corp. (PROF) Profound Medical's primary market focus for its TULSA-PRO® system is the United States. Revenue distribution data highlights this concentration, with approximately 81% of revenues for the nine months ended September 30, 2024, generated in the US, compared to 11% in the EU and 8% in Asia. This marks an increase in the US revenue share from 69% in the prior year. Similarly, for the three months ended March 31, 2024, the US accounted for 61% of revenues, the EU for 34%, and Asia for 5%.1 While the company maintains a limited European commercial effort, it continues to focus primarily on the US market for TULSA-PRO® sales.1 Profound's Sonalleve® product, however, is marketed predominantly outside North America, particularly in European and Asian countries.1 Clinical trials, such as the CAPTAIN trial, are also primarily conducted in the United States, with additional sites in Canada and Europe.1

EDAP TMS S.A. (EDAP) Specific granular data on the geographical distribution of EDAP's Focal One® Robotic HIFU platform's installed base is not explicitly detailed in the available Fintel search results. However, EDAP has stated its intention for "continued global expansion" of its Focal One® platform, with the system being introduced in both Europe and the U.S.2 The recent €36 million credit facility from the European Investment Bank (EIB) is earmarked to support this global expansion and accelerate the development of new clinical indications.2 This indicates a broad international strategy, rather than a concentrated focus on a single region like Profound's emphasis on the US for TULSA-PRO®.

Market Focus and Expansion Opportunities

• Profound Medical Corp. (PROF): The significant revenue concentration in the US for TULSA-PRO® suggests that this remains the key market for immediate growth and expansion. The company's strategy involves cultivating adoption of TULSA-PRO® technology, supporting clinical customers, and increasing system utilization within the US.3 While Sonalleve® provides a foothold in European and Asian markets, the TULSA-PRO® system's growth is heavily weighted towards North America.
• EDAP TMS S.A. (EDAP): EDAP's strategic financing from the EIB points to a more diversified, global expansion strategy. The focus on developing new clinical indications for its HIFU technology implies broader market opportunities beyond prostate cancer, potentially opening new geographical markets as these indications gain regulatory approval and adoption.2

In essence, Profound Medical has a well-defined primary market (US for TULSA-PRO®) with secondary efforts in Europe and Asia. EDAP, while present in Europe and the US, appears to be pursuing a more generalized global expansion for its core Focal One® platform, backed by substantial investment to achieve this.

What are the comparable costs to install each system? Who are the purchasers: hospitals? clinics? or privately held treatment centers? What are the revenues per procedure? Are the procedures covered by patient medical insurance or medicaid/medicare?